Emergent BioSolutions (EBS) Gross Profit (2011 - 2026)

Emergent BioSolutions' Gross Profit history runs 16 years deep, the most recent figure standing at $84.1 million for Q1 2026.

• On a quarterly basis, Gross Profit fell 37.1% year-over-year to $84.1 million in Q1 2026; TTM through Mar 2026 was $367.1 million, a 3.8% decrease from a year earlier, with the FY2025 full-year figure at $416.7 million, up 15.02% from the prior year.
• Gross Profit climbed to $84.1 million in Q1 2026 per EBS's latest filing, from $63.8 million in the prior quarter.
• Across five years, Gross Profit topped out at $224.5 million in Q1 2022 and bottomed at $11.4 million in Q1 2023.
• The 5-year median for Gross Profit is $113.7 million (2023), against an average of $118.2 million.
• Across the five-year window, Gross Profit tumbled 94.92% in 2023 and soared 1266.67% in 2024, its largest moves.
• Year by year, Gross Profit stood at $162.9 million in 2022, then plunged by 43.83% to $91.5 million in 2023, then dropped by 16.17% to $76.7 million in 2024, then retreated by 16.82% to $63.8 million in 2025, then jumped by 31.82% to $84.1 million in 2026.
• Per Business Quant, the three latest EBS Gross Profit figures stand at $84.1 million (Q1 2026), $63.8 million (Q4 2025), and $145.2 million (Q3 2025).